On 1 July 2010 SWIP changed the manager selection process for this fund. It is now controlled in-house by the SWIP Multi-Manager team. Consequently the Fund has been restructured with several external manager replacements.
Fund objective
The Multi-Manager UK Equity Income Fund is designed to provide investors with broad exposure to the UK equity market with a focus on income generation. The Fund aims to add value above the total return of the FTSE All-Share Index through active stock selection. The Fund will be in the IMA UK Equity Income Universe.
You should note that the value of your investment can go down as well as up and investors may not get back the full amount invested.
The Fund may have holdings which are denominated in different currencies and may be affected by movements in exchange rates. Consequently, the value of the investment may rise or fall in line with the exchange rates.
Further details of the specific risks relating to investment in a Fund can be found in the relevant Prospectus and the Simplified Prospectus or Key Investor Information Document (KIID).
Literature
Fund performance (calendar years)
| Fund/index return |
Since inception |
2012** |
2010 |
2010 |
2009 |
2008 |
| Fund return % |
5.5 |
5.3 |
-0.6 |
12.4 |
22.3 |
-31.0 |
| *FTSE All Share % |
7.2 |
6.1 |
-3.5 |
14.5 |
30.1 |
-29.9 |
| Median return % |
5.9 |
6.3 |
-3.7 |
13.5 |
22.2 |
-28.1 |
Source: Lipper, net of fees. *SWIP.
Past performance is not a guide to future performance
**Year to date figure.
Inception for performance calculation this is demeed as 01/11/04
Fund information
| Fund launch date |
18 October 2004 |
| Fund manager |
Lyndon Gill |
| Fund size |
£1.2bn |
| Base currency |
GBP |
| Benchmark |
FTSE All-Share Index |
| IMA sector |
UK All Companies |
| Income yield |
4.2% |
| Valuation point |
12:00 noon |
| SWIP code |
45400 |
| ISIN codes |
A Acc - GB00B02G7936
A Inc - GB00B0JVJR34 |
| SEDOL codes |
A Acc - B02G793
A Inc - B0JVJR3 |
| Bloomberg code |
A Acc - MMUKEIA LN |
|
GlaxoSmithKline |
5.7% |
|
Royal Dutch Shell |
5.6% |
| Vodafone |
4.4% |
| British American Tobacco |
3.8% |
| Unilever |
2.9% |
| AstraZeneca |
2.8% |
| BT Group |
2.7% |
|
Imperial Tobacco |
2.7% |
| HSBC Holdings |
2.5% |
| Centrica |
1.9% |
Source: SWIP
All data as at 31 March 2012 unless otherwise stated